Cargando…
NI‐0801, an anti‐chemokine (C‐X‐C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid
NI‐0801 is a fully human monoclonal antibody against chemokine (C‐X‐C motif) ligand 10 (CXCL10), which is involved in the recruitment of inflammatory T cells into the liver. The safety and efficacy of NI‐0801 was assessed in patients with primary biliary cholangitis. In this open‐label phase 2a stud...
Autores principales: | de Graaf, Kathy L., Lapeyre, Geneviève, Guilhot, Florence, Ferlin, Walter, Curbishley, Stuart M., Carbone, Marco, Richardson, Paul, Moreea, Sulleman, McCune, C. Anne, Ryder, Stephen D., Chapman, Roger W., Floreani, Annarosa, Jones, David E., de Min, Cristina, Adams, David H., Invernizzi, Pietro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944576/ https://www.ncbi.nlm.nih.gov/pubmed/29761166 http://dx.doi.org/10.1002/hep4.1170 |
Ejemplares similares
-
Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis
por: Floreani, Annarosa
Publicado: (2020) -
Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020) -
Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review
por: Li, Xuan, et al.
Publicado: (2020) -
A randomized, controlled trial on fenofibrate in primary biliary
cholangitis patients with incomplete response to ursodeoxycholic
acid
por: Li, Chunlei, et al.
Publicado: (2022) -
Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)